JP2022500047A5 - - Google Patents
Info
- Publication number
- JP2022500047A5 JP2022500047A5 JP2021514036A JP2021514036A JP2022500047A5 JP 2022500047 A5 JP2022500047 A5 JP 2022500047A5 JP 2021514036 A JP2021514036 A JP 2021514036A JP 2021514036 A JP2021514036 A JP 2021514036A JP 2022500047 A5 JP2022500047 A5 JP 2022500047A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- genetically modified
- rat
- microns
- compared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730690P | 2018-09-13 | 2018-09-13 | |
| US62/730,690 | 2018-09-13 | ||
| PCT/US2019/050792 WO2020056122A1 (en) | 2018-09-13 | 2019-09-12 | Complement factor h gene knockout rat as a model of c3 glomerulopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500047A JP2022500047A (ja) | 2022-01-04 |
| JP2022500047A5 true JP2022500047A5 (enExample) | 2022-09-01 |
| JP7222075B2 JP7222075B2 (ja) | 2023-02-14 |
Family
ID=68052023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514036A Active JP7222075B2 (ja) | 2018-09-13 | 2019-09-12 | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12653168B2 (enExample) |
| EP (1) | EP3849304B1 (enExample) |
| JP (1) | JP7222075B2 (enExample) |
| KR (1) | KR102545031B1 (enExample) |
| CN (1) | CN112969367B (enExample) |
| AU (1) | AU2019339404B2 (enExample) |
| CA (1) | CA3112612C (enExample) |
| ES (1) | ES2974200T3 (enExample) |
| WO (1) | WO2020056122A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12653168B2 (en) | 2018-09-13 | 2026-06-16 | Regeneron Pharmaceuticals, Inc. | Complement factor H gene knockout rat as a model of C3 glomerulopathy |
| GB202010009D0 (en) * | 2020-06-30 | 2020-08-12 | Syncona Investment Man Ltd | Vector |
| CN114634932B (zh) * | 2022-03-11 | 2023-09-05 | 安徽医科大学 | 一种新circRNA、试剂盒及用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| WO1999005266A2 (en) | 1997-07-26 | 1999-02-04 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AUPR451401A0 (en) | 2001-04-20 | 2001-05-24 | Monash University | A method of nuclear transfer |
| US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
| EP2465534B1 (en) * | 2004-06-10 | 2017-03-29 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| US7745389B2 (en) | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| CN101117633B (zh) | 2006-08-03 | 2011-07-20 | 上海交通大学附属儿童医院 | 一种细胞核移植方法 |
| KR20100120226A (ko) | 2008-04-11 | 2010-11-12 | 유티씨 파워 코포레이션 | 매니폴드 섬프를 갖는 바이폴라 플레이트 및 연료 전지 |
| US8476032B2 (en) * | 2008-08-27 | 2013-07-02 | Children's Hospital & Research Center Oakland | Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis |
| US20120159653A1 (en) * | 2008-12-04 | 2012-06-21 | Sigma-Aldrich Co. | Genomic editing of genes involved in macular degeneration |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| GB0922659D0 (en) | 2009-12-24 | 2010-02-10 | Univ Edinburgh | Factor H |
| ES2683071T3 (es) | 2012-04-25 | 2018-09-24 | Regeneron Pharmaceuticals, Inc. | Direccionamiento mediado por nucleasas con grandes vectores de direccionamiento |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| WO2014033644A2 (en) | 2012-08-28 | 2014-03-06 | Novartis Ag | Methods of nuclease-based genetic engineering |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| MX2015010841A (es) | 2013-02-20 | 2016-05-09 | Regeneron Pharma | Modificacion genetica de ratas. |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| EP3003372B1 (en) * | 2013-06-07 | 2019-10-09 | Duke University | Inhibitors of complement factor h |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| MX388127B (es) | 2013-12-11 | 2025-03-19 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| US9738897B2 (en) | 2014-06-23 | 2017-08-22 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated DNA assembly |
| DK3161128T3 (en) | 2014-06-26 | 2018-11-05 | Regeneron Pharma | METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| EP3221457B1 (en) | 2014-11-21 | 2019-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
| WO2017114401A1 (zh) * | 2015-12-31 | 2017-07-06 | 江苏匡亚生物医药科技有限公司 | 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用 |
| CN106519030B (zh) * | 2016-12-22 | 2020-01-07 | 广州泰诺迪生物科技有限公司 | 补体因子h抑制剂及与之相关的用途 |
| KR20260069620A (ko) * | 2017-01-30 | 2026-05-15 | 알렉시온 파마슈티칼스, 인코포레이티드 | 1가 항-프로페르딘 항체 및 항체 단편 |
| WO2018157027A1 (en) * | 2017-02-27 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Humanized model of kidney and liver disorders |
| US12653168B2 (en) | 2018-09-13 | 2026-06-16 | Regeneron Pharmaceuticals, Inc. | Complement factor H gene knockout rat as a model of C3 glomerulopathy |
-
2019
- 2019-09-12 US US17/275,096 patent/US12653168B2/en active Active
- 2019-09-12 CA CA3112612A patent/CA3112612C/en active Active
- 2019-09-12 KR KR1020217010579A patent/KR102545031B1/ko active Active
- 2019-09-12 EP EP19773717.4A patent/EP3849304B1/en active Active
- 2019-09-12 AU AU2019339404A patent/AU2019339404B2/en active Active
- 2019-09-12 JP JP2021514036A patent/JP7222075B2/ja active Active
- 2019-09-12 CN CN201980071118.4A patent/CN112969367B/zh active Active
- 2019-09-12 WO PCT/US2019/050792 patent/WO2020056122A1/en not_active Ceased
- 2019-09-12 ES ES19773717T patent/ES2974200T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sequeira-Lopez et al. | The microRNA-processing enzyme dicer maintains juxtaglomerular cells | |
| US12471579B2 (en) | Mouse model of DITRA disease and uses thereof | |
| JP2021500864A5 (enExample) | ||
| Paratz et al. | Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon? | |
| JP2020501582A5 (enExample) | ||
| KR102602199B1 (ko) | 신장 및 간 장애의 인간화 모델 | |
| JP7473548B2 (ja) | Ｍｍａの処置のための非破壊的遺伝子治療 | |
| WO2018057790A1 (en) | Animal models for cardiomyopathy | |
| JP2019500347A5 (enExample) | ||
| CN112011538A (zh) | 一种Mutyh基因条件性敲除小鼠模型的构建方法 | |
| US7960606B2 (en) | Mouse model of chronic heart failure and coronary atherosclerosis regression | |
| Chey et al. | CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies | |
| Hashikami et al. | Establishment of X-linked Alport syndrome model mice with a Col4a5 R471X mutation | |
| Aweidah et al. | PRPF31-retinitis pigmentosa: Challenges and opportunities for clinical translation | |
| WO2013188358A1 (en) | Miniature swine transgenic for one or more coagulation factors | |
| CN111485003B (zh) | 一种视网膜血管疾病模型的构建方法及其应用 | |
| CN116676338A (zh) | 一种遗传型转甲状腺素蛋白淀粉样变疾病模型的构建方法及应用 | |
| JP7222075B2 (ja) | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット | |
| Ding et al. | Genetic evidence that lethality in angiotensinogen-deficient mice is due to loss of systemic but not renal angiotensinogen | |
| US20200009180A1 (en) | Methods of treating alzheimer's disease | |
| CN115838768A (zh) | 一种基因敲除能够引起癫痫症状发生的动物模型构建的方法及应用 | |
| KR20220150295A (ko) | B4galt1-매개 기능의 설치류 모델 | |
| CN114107400B (zh) | 一种视网膜血管疾病模型的构建方法及其应用 | |
| US20260078368A1 (en) | Methods and compositions for treating pancreatic cancer | |
| CN116064526B (zh) | 靶向stat3基因的向导rna、试剂盒、方法及应用 |